In the current study, the efficacy of epalrestat for diabetic retinopathy/nephropathy was examined by re-analysis of the results of the Aldose Reductase Inhibitor–Diabetes Complications Trial, with consideration of the influence of patient background factors and severity of diabetic neuropathy. This evidence concerns the gene AKR1B1 and kidney disorder.